It is found that PD-L2 is upregulated in isolated senescent human cells and during aging, and senolytics can remove age-associated, highly PD-L2-expressing senescent cells.
Abstract
Senescent cells, which are normally cleared by the immune system but accumulate with age, contribute to multiple disorders including metabolic dysfunction and impaired fitness. While immune checkpoint inhibitors have been well studied in cancer, the role of programmed cell death ligand 2 (PD-L2) in non-cancerous, age-associated cellular senescence remains unclear. We found that PD-L2 is upregulated in isolated senescent human cells and during aging, and senolytics can remove age-associated, highly PD-L2-expressing senescent cells. Old PD-L2 knockout mice accumulate fewer senescent cells than old wild-type mice, and their insulin sensitivity and grip strength are greater. Anti-PD-L2 therapy restored insulin sensitivity in aged wild-type mice. PD-L2 acts as an immune checkpoint on senescent cells, allowing them to evade immune clearance and promoting their persistence during aging. Targeting PD-L2 in senescent cells may be a strategy for alleviating the age-related dysfunction associated with cellular senescence.
Autophagy dysfunction and senescence are established drivers of aging, but their potential interaction remains poorly understood. Here we show that age-related decline of chaperone-mediated autophagy (CMA), a pathway for selective lysosomal protein degradation, changes senescent cell properties and impairs their immune...
Rebecca Sereda, Kristen Lindenau, Antonio Díaz et al.· Nature Aging· 1 citation
This review summarizes current evidence suggesting that senescent cells persistence is attributable not only to immune system decline but also to active, cell-intrinsic mechanisms of immune evasion and highlights emerging therapeutic strategies aimed at targeting the immune evasion of senescent cells.
Qikun Ou, Jin-Ran Zhao, Yuanlong Ge et al.· Ageing and Cancer Research &...· 0 citations
Immune checkpoint inhibitor (ICI) therapy triggers complications that are currently attributed solely to immune activation. We hypothesized that target tissue–specific mechanisms also play a role and studied these mechanisms in thyrocytes. We found that thyroidal PD-L1 acts as a cytoprotective regulator, promoting cell...
Mihaela Stefan-Lifshitz, Nicola Viola, O. Meshcheryakova et al.· Science Advances· 0 citations
The aged tumor microenvironment can impair antitumor T cell function, but the molecular regulators that become limiting in this setting remain poorly defined. In a recent issue of Cell, Chen and colleagues harness in vivo CRISPR screening to compare the effects of genetic perturbations in tumor-reactive CD8+ T cells ac...
Brian Oh, Corina Amor· Cancer Research· 0 citations
It is suggested that bidirectional disruptions to normal LRRK2 function break immune homeostasis and immune cell function should be carefully considered when targeting LRRK2 kinase activity in patients with PD.
Robert C. Sharp, Shannon C. Wall, Jordan C. Follet et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.